Laura Breidinger
Payments from drug & device makers
Across 359 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$973
- AstraZeneca$854
- Lilly USA, LLC$682
- AbbVie$585
- Astellas Pharma US Inc$551
- Bayer$451
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,09496%
- Education$2754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $973 |
| AstraZeneca | 46 | $854 |
| Lilly USA, LLC | 39 | $682 |
| AbbVie | 27 | $585 |
| Astellas Pharma US Inc | 15 | $551 |
| Bayer | 33 | $451 |
| GSK | 38 | $437 |
| Boehringer Ingelheim | 14 | $270 |
| Pfizer | 11 | $193 |
| Amgen(2 entities) | 8 | $151 |
| Teva Pharmaceuticals USA, Inc. | 7 | $145 |
| Sanofi-aventis U.S. LLC | 7 | $126 |
| Exact Sciences | 7 | $119 |
| Otsuka America Pharmaceutical, Inc. | 6 | $119 |
| Abbott | 7 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Amarin Pharma, Inc. | 4 | $74 |
| Merck | 3 | $49 |
| Philips North America LLC | 2 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Corcept Therapeutics | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Vertex | 1 | $26 |
| Novartis | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
How this compares
$6,369 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $136,788 |
| JardianceEmpagliflozin | 89 | $134,706 |
| EliquisApixaban | 94 | $128,801 |
| MounjaroTirzepatide | 64 | $91,130 |
| TrulicityDulaglutide | 49 | $81,570 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $74,420 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $34,949 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $26,224 |
| MultaqDronedarone Hcl | 11 | $23,412 |
| MyrbetriqMirabegron | 27 | $21,527 |
| FarxigaDapagliflozin Propanediol | 18 | $20,591 |
| XareltoRivaroxaban | 19 | $14,134 |
| LinzessLinaclotide | 13 | $12,848 |
| Mirabegron ErMirabegron | 12 | $12,769 |
| JanuviaSitagliptin Phosphate | 11 | $10,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $682 | $172,700113 claims |
| Novo NordiskOzempic | $973 | $136,78867 claims |
| Boehringer IngelheimJardiance | $270 | $134,70689 claims |
| PfizerEliquis | $193 | $128,80194 claims |
| GSKTrelegy Ellipta, Shingrix | $437 | $76,54859 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $854 | $46,81550 claims |
| Sanofi-aventis U.S. LLCMultaq | $126 | $23,41211 claims |
| Astellas Pharma US IncMyrbetriq | $551 | $21,52727 claims |
| AbbVieLinzess, Synthroid | $585 | $15,02733 claims |
| MerckJanuvia | $49 | $10,95411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Caro
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.